Kinera: Ischemic Disease
a life-threatening condition that occurs when there is a restriction in the
vessels supplying blood and oxygen to organs. In the tissues of the brain and
heart restriction of oxygen supply can cause irreversible damage and death may
occur within minutes if left untreated.
holds a strong patent portfolio around the novel use of midkine (MK) in the
treatment and prevention of ischemic diseases. The Company, in collaboration
with PharmaHungary has a pre-clinical program in place (CMK103) to evaluate MK
in the treatment of acute and chronic myocardial infarction (MI).
disease is a major global health issue, with over 32.4 million myocardial
infarctions and strokes worldwide each year.
Cardiovascular diseases are the number one cause of death worldwide
representing 31% of all deaths (17.3 million p.a, expected to rise to 23.6 million
by 2030). Of these deaths 7.4 million
are due to coronary heart disease. Not
all cardiovascular ischemic events are fatal, with many patients surviving and
progressing to further ischemic events (which make up 30% of total events), and
many patients experience progressive and debilitating consequences that
eventually lead to death.
CMK103 treatment aims to meet the vast and currently unmet need for new
compounds that reduce the damage to tissues that occur after a heart attack.
The damage to the heart muscle can lead to progressive heart failure and
reducing the initial damage can improve long term outcomes. Research has shown that acute and
chronic treatment with MK protein prevents cell death, also known as apoptosis,
and protects the muscle from dysfunctional remodelling. The treatment not only reduces acute mortality,
but results in improved long term cardiac outputs and reduced longer term
mortality in animal models. Cellmids CMK103 is the only known compound
with both anti-apoptotic and pro-angiogenic properties for the treatment of MI.
cost and healthcare burden of cardiovascular and ischemic diseases is highly
significant and will increase as the population ages. In the West, an increasing proportion of the
population is entering the high risk age group of those 65 and older; 23% of
the Australian population will be in this age group by 2050. As it stands, the direct and indirect costs
of cardiovascular disease and stroke are estimated to be US$ 320.1 billion in
the USA and AUD$ 17.9 billion in Australia, while the direct cost of myocardial
infarcts in the UK accounts for 1% of the entire NHS budget.
The total global market for drugs for
ischemic heart disease is expected to reach US$20 billion by 2020. Cellmid’s
CMK103 treatment has strong potential to position itself within this drug
market. Following from this, and guided
by our cardiac program, Cellmid hopes to explore the use of midkine for the
treatment of stroke.